CD8A and non-small cell lung carcinoma: Bemcentinib restored pembrolizumab sensitivity of STK11/LKB1 mutant NSCLC through expansion of PD-1+ CD8+ T cells [44], and it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) in STK11 mutated advanced metastatic NSCLC [43].